Drug Profile
Daniluromer - Edesa Biotech
Alternative Names: EB-01Latest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Edesa Biotech
- Class Anti-inflammatories; Nonsteroidal anti-inflammatories; Skin disorder therapies
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Contact dermatitis